Trial Profile
A Double Blind, Placebo Controlled Study of the Effect of 330 mg QD of TRO19622 in the Treatment of Chemotherapy Induced Peripheral Neuropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Olesoxime (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms CIPN
- Sponsors Roche; Trophos
- 27 Dec 2012 Status changed from unconfirmed to completed as reported by ClinicalTrials.gov.
- 12 Jul 2012 Status changed from recruiting to unconfirmed.
- 17 Apr 2009 New trial record